Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists win £800,000 to boost research into fighting viruses

15.03.2005


A team of University of Glasgow scientists have received a grant of £800,000 from the Wellcome Trust to research a mechanism that blocks a critical step in the replication cycle of retroviruses. In the long term, the research could lead to the design of new therapeutic strategies or drugs against retroviruses, which cause diseases such as AIDS and certain leukemias.



Mammals have evolved several mechanisms to fight viral infections, and insight into how humans and animals successfully limit virus spread helps to develop effective anti-viral drugs and vaccines.

The scientists are set to further investigate a mechanism that may be able to stop so-called retroviruses in their tracks. Retroviruses, during their life cycle, spread by permanently inserting their genetic material into healthy cell’s DNA.


The scientists, led by Professor Massimo Palmarini from the University of Glasgow’s Faculty of Veterinary Medicine, are investigating how some endogenous retroviruses (’benign’ retrovirusese present in the genome of all mammals) protect hosts by interfering with the infection by related disease-causing retroviruses.

The new grant will boost the study of how an ’endogenous’ retroviruses (ERV) named enJS56A1 interferes with a pathogenic ’exogenous’ retrovirus (JSRV), the cause of major infectious diseases of sheep. enJS56A1 forms viral particles that ’stick’ together and cannot exit the cell and spread to other cells. JSRV instead forms particles normally able to exit the cell.

However, when JSRV and enJS56A1 are present in the same cell only defective ’sticky particles’ are formed, effectively blocking viral infection. Understanding the mechanisms of enJS56A1-induced block can lay the foundation to develop new drugs that stop production of viruses from infected cells.

The research is set to shed light on how retroviruses evolve and will help explain late steps in the retroviral life cycle. Understanding how enJS56A1 functions could provide a model for designing new anti-retroviral therapies that work on cells already infected by retroviruses. Many current anti-retroviral drugs function only immediately after the virus infects a new cell.

Professor Palamarini, from the University of Glasgow’s Veterinary Faculty, said: ’The grant is set to develop much needed research into viral infections. We need to understand more about how retroviruses work and this work could eventually lead to new treatments to fight retroviruses.’

’Like all viruses, retroviruses insert their genetic material into host cells and then force the host to make copies of the virus. Unlike other viruses, however, retroviruses permanently insert a copy of their genes into the genome of cells they invade. Every sheep on the planet has retroviruses that are present in the genome like every other gene. In fact, all animal species - humans included - have retroviruses that are genetically inherited.’

The University of Glasgow recently recruited Professor Massimo Palmarini, a world-leading expert in viral pathogenesis and lung cancer. Most recently of the University of Georgia, USA, Professor Palmarini now leads a team of molecular cancer specialists and virologists at Glasgow and is set to continue his groundbreaking work into a virus induced type of lung cancer, the disease which led to the demise of Dolly the sheep, the world’s first cloned mammal.

His expertise spans the fields of viral pathogenesis, infectious disease and cancer. The major focus of Professor Palmarini’s research is the study of a naturally occurring contagious lung cancer of sheep, ovine pulmonary adenocarcinoma (OPA) that cannot currently be controlled, and leads to significant economic loss in the UK and beyond. Research into the mechanisms underlying this form of lung cancer could provide strategies to understand the onset and progression of human lung cancer, the leading cause of deaths in cancer patients.

Jenny Murray | alfa
Further information:
http://www.gla.ac.uk:443/newsdesk/pressreleases/stories.cfm?PRID=3216

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>